Days after FDA Commissioner Marty Makary appeared to malign uniQure’s AMT-130 in an interview with CNBC, the agency confirmed ...
As Novo Nordisk continues to lose ground in the obesity market to rival Eli Lilly, the Danish company has started ...
Aardvark Therapeutics is down 54% since Friday after the biotech said it detected “reversible cardiac observations” in a ...
Yuviwel will compete with BioMarin’s Voxzogo. Meanwhile, BridgeBio is working to bring its own achondroplasia drug, the FGFR3 ...
One of the two new members of the CDC's Advisory Committee on Immunization Practices questioned the safety of COVID-19 ...
Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...
On the FDA’s docket this month are two decisions pushed back from 2025, including one for a rare form of obesity and another ...
The CDC’s changes threaten to cut vaccine sales for makers including Pfizer, Moderna, Merck and more, but a legal expert ...
This week’s Capitol Hill meetings come on the heels of rejections of ultra-rare disease drugs developed by Biohaven and Saol ...
FDA Commissioner Marty Makary presented a new idea to staff this week: bonus payments for employees that complete regulatory ...
Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results